I would think so. There wasn't that many if I'm not
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Protecting Shareholder Rights: iRhythm Technologies Update
Understanding Your Rights as a Shareholder For shareholders of iRhythm Technologies, Inc. (NASDAQ: IRTC), it's imperative to be proactive regarding your rights. Engaging with legal experts can significantly empower your ability to affect change and seek justice for any personal or collective grievances stemming from corporate actions. Why Shareholder Action is Crucial...
Continue Reading
Discover the New Credit Risk IQ and its Industry Insights
Introducing Credit Risk IQ Credit Benchmark, a leader in delivering essential credit risk data and analytics, has launched an exciting new platform called Credit Risk IQ. This online portal features an extensive library of over 5,000 free monthly reports that explore credit trends at both industry and sector levels. The insights found in these reports are invaluable for...
Continue Reading
9Rooftops Retained as Marketing Agency for South Carolina Tourism
9Rooftops Reappointed for South Carolina Tourism Marketing 9Rooftops, known for its innovative marketing strategies, has been reappointed as the Marketing and Advertising Agency of Record for the South Carolina Department of Parks, Recreation & Tourism (SCPRT). This marks a continued partnership aimed at showcasing the beauty and attractions of South Carolina. A...
Continue Reading
Kyivstar Enhances Digital Services with AI Cloud Solutions
Kyivstar Revolutionizes Cloud Services with AI Integration Kyivstar Group Ltd (Nasdaq: KYIV; KYIVW) has embarked on an ambitious journey to strengthen digital services within Ukraine. The company has officially announced the integration of groundbreaking artificial intelligence (AI) technologies into its cloud platform, Kyivstar Cloud. This advancement is pivotal for all...
Continue Reading
Akeso Advances Cancer Care with Ivonescimab Phase III Trial Launch
Akeso Launches Phase III Trial for Ivonescimab in SCLC Akeso, Inc. (9926.HK) recently announced an exciting milestone in cancer treatment with the first patient being dosed in its Phase III clinical trial. This multicenter, randomized, and double-blind study, named AK112-311/HARMONi-9, evaluates the efficacy and safety of ivonescimab, a unique bispecific antibody that...
Continue Reading